Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multippel sklerose, relapsing-remitting - immunosuppressants, selektiv immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostata neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Norge - norsk - Statens legemiddelverk

mcneil sweden ab - budesonid - nesespray, suspensjon - 64 mikrog/ dose

Norge - norsk - Statens legemiddelverk

mcneil sweden ab - budesonid - nesespray, suspensjon - 32 mikrog/ dose

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - daptomycin - pulver til injeksjons-/infusjonsvæske, oppløsning - 500 mg

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - midazolamhydroklorid - injeksjons-/infusjonsvæske, oppløsning i ferdigfylt sprøyte - 1 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofunginacetat - candidiasis; aspergillosis - antimykotika for systemisk bruk - behandling av invasiv candidiasis i voksen eller paediatric pasienter. behandling av invasive aspergillosis i voksen eller paediatric pasienter som er refraktære til eller intolerante av amfotericin b, lipid formuleringer av amfotericin b og/eller itrakonazol. refraktivitet er definert som progresjon av infeksjon eller unnlatelse av å forbedre etter minimum 7 dager før terapeutiske doser av effektive soppdrepende behandling. empirisk behandling for antatte fungal infeksjoner (for eksempel candida eller aspergillus) i febrile, neutropaenic voksen eller paediatric pasienter.

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - doksorubicinhydroklorid - konsentrat til infusjonsvæske, oppløsning - 2 mg/ ml

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - olanzapin - tablett, filmdrasjert - 2.5 mg